Abstract 98
| Maintenance of remission, n (%) | |||
|---|---|---|---|
| Week | Placebo (n = 18) | ADA 40 mg eow (n = 19) | ADA 40 mg/week (n = 18) |
| LOCF, *p<0.05 adalimumab v placebo. | |||
| 4 | 16 (89) | 18 (95) | 18 (100) |
| 12 | 10 (56) | 17 (90)* | 16 (89)* |
| 24 | 9 (50) | 16 (84)* | 17 (94)* |
| 32 | 7 (39) | 16 (84)* | 18 (100)* |
| 48 | 8 (44) | 14 (74)* | 17 (94)* |
| 56 | 8 (44) | 14 (74) | 15 (83)* |